Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

JNJ-40411813

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
ABSTRACT Introduction: Positive allosteric modulation of mGlu2 has attracted much interest as an alternative approach to… Expand
Review
2018
Review
2018
The Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV) took place in Madrid, Spain, on May 13‐16… Expand
2017
2017
The metabotropic glutamate receptor subtype 2 (mGlu2) possesses both orthosteric and allosteric modulatory sites, are expressed… Expand
Review
2017
Review
2017
Clinical and preclinical studies suggest that dysfunction of the glutamatergic system is implicated in mood disorders such as… Expand
  • figure 1
  • table 1
2016
2016
Alterations in rapid eye movement sleep (REM) have been suggested as valid translational efficacy markers: activation of the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
This phase 2a, randomized, multicenter, double-blind, proof-of-concept study was designed to evaluate, efficacy, safety and… Expand
2015
2015
JNJ‐40411813/ADX71149 (1‐butyl‐3‐chloro‐4‐(4‐phenylpiperidin‐1‐yl) pyridin‐2(1H)‐one) is a positive allosteric modulator (PAM) of… Expand
2015
2015
Compounds modulating metabotropic glutamate type 2 (mGlu2) receptor activity may have therapeutic benefits in treating… Expand
2015
2015
Metabotropic glutamate receptor-2 positive allosteric modulator, JNJ-40411813 (ADX71149), was characterised for clinical effects… Expand
  • figure 1
  • table 1
  • figure 2
  • table 3
  • table 4
2014
2014
We previously reported the discovery of 4-aryl-substituted pyridones with mGlu2 PAM activity starting from the HTS hit 5. In this… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4